Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.

<p class="MsoNormal" style="margin: 1pt 7.0865pt; text-align: justify;"><strong><span style="font-weight: bold; font-family: Tahoma;">Background</span></strong><span style="font-family: Tahoma;"><strong>:</strong>...

Full description

Saved in:
Bibliographic Details
Main Authors: Leslie Pérez Ruiz, Ana María Ramos Cedeño, José Cabrera Gómez, Nancy Echazábal Santana, Hailen Bobillo López
Format: Article
Language:Spanish
Published: Centro Provincial de Información de Ciencias Médicas. Cienfuegos 2007-12-01
Series:Medisur
Subjects:
Online Access:http://medisur.sld.cu/index.php/medisur/article/view/288
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832577319584137216
author Leslie Pérez Ruiz
Ana María Ramos Cedeño
José Cabrera Gómez
Nancy Echazábal Santana
Hailen Bobillo López
author_facet Leslie Pérez Ruiz
Ana María Ramos Cedeño
José Cabrera Gómez
Nancy Echazábal Santana
Hailen Bobillo López
author_sort Leslie Pérez Ruiz
collection DOAJ
description <p class="MsoNormal" style="margin: 1pt 7.0865pt; text-align: justify;"><strong><span style="font-weight: bold; font-family: Tahoma;">Background</span></strong><span style="font-family: Tahoma;"><strong>:</strong> The </span><span style="font-family: Tahoma;">interferon </span><span style="font-family: Tahoma;">alpha 2b recombinant, produced in Cuba, is used in the treatment of different illnesses, such as the multiple sclerosis. For its commercialization it is needed to know its safety scope. </span><strong><span style="font-weight: bold; font-family: Tahoma;">Objective</span></strong><span style="font-family: Tahoma;"><strong>:</strong> To assess the adverse reactions of interferon alpha 2b recombinant in the treatment of multiple sclerosis. </span><strong><span style="font-weight: bold; font-family: Tahoma;">Method:</span></strong><span style="font-family: Tahoma;"> During the period between 1996 and 2006, 70 clinical histories and data collection notebooks of patients included in the randomized double blind national clinical trial phase IV were revised. This trial was developed in the Clinic of Multiple Sclerosis of the Hospital "Dr. Gustavo Aldereguía Lima" in Cienfuegos. With regard to the total of manifested adverse reactions we analyzed type, length, and use of a given treatment to counteract them, intensity level (light, moderate, serious or lethal) and causality level (definitive, probable, possible, conditional or not related). </span><strong><span style="font-weight: bold; font-family: Tahoma;">Results:</span></strong><span style="font-family: Tahoma;"> 53 patients out of the total presented 207 adverse reactions to interferon. The most frequent were: fever, migraine, chills, arthralgia, asthenia and myalgia, being most of them moderate collateral effects of definitive character. In 197 patients the outcome was favorable. </span><strong><span style="font-weight: bold; font-family: Tahoma;">Conclusion</span></strong><span style="font-family: Tahoma;"><strong>:</strong> The use of the interferon alpha 2b recombinant was safe in the treatment of the multiple sclerosis in these patients.</span></p><p class="MsoNormal"> </p>
format Article
id doaj-art-628c98a57aa24f24914e65e4a127a54a
institution Kabale University
issn 1727-897X
language Spanish
publishDate 2007-12-01
publisher Centro Provincial de Información de Ciencias Médicas. Cienfuegos
record_format Article
series Medisur
spelling doaj-art-628c98a57aa24f24914e65e4a127a54a2025-01-30T21:28:39ZspaCentro Provincial de Información de Ciencias Médicas. CienfuegosMedisur1727-897X2007-12-01531822287Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.Leslie Pérez RuizAna María Ramos CedeñoJosé Cabrera GómezNancy Echazábal SantanaHailen Bobillo López<p class="MsoNormal" style="margin: 1pt 7.0865pt; text-align: justify;"><strong><span style="font-weight: bold; font-family: Tahoma;">Background</span></strong><span style="font-family: Tahoma;"><strong>:</strong> The </span><span style="font-family: Tahoma;">interferon </span><span style="font-family: Tahoma;">alpha 2b recombinant, produced in Cuba, is used in the treatment of different illnesses, such as the multiple sclerosis. For its commercialization it is needed to know its safety scope. </span><strong><span style="font-weight: bold; font-family: Tahoma;">Objective</span></strong><span style="font-family: Tahoma;"><strong>:</strong> To assess the adverse reactions of interferon alpha 2b recombinant in the treatment of multiple sclerosis. </span><strong><span style="font-weight: bold; font-family: Tahoma;">Method:</span></strong><span style="font-family: Tahoma;"> During the period between 1996 and 2006, 70 clinical histories and data collection notebooks of patients included in the randomized double blind national clinical trial phase IV were revised. This trial was developed in the Clinic of Multiple Sclerosis of the Hospital "Dr. Gustavo Aldereguía Lima" in Cienfuegos. With regard to the total of manifested adverse reactions we analyzed type, length, and use of a given treatment to counteract them, intensity level (light, moderate, serious or lethal) and causality level (definitive, probable, possible, conditional or not related). </span><strong><span style="font-weight: bold; font-family: Tahoma;">Results:</span></strong><span style="font-family: Tahoma;"> 53 patients out of the total presented 207 adverse reactions to interferon. The most frequent were: fever, migraine, chills, arthralgia, asthenia and myalgia, being most of them moderate collateral effects of definitive character. In 197 patients the outcome was favorable. </span><strong><span style="font-weight: bold; font-family: Tahoma;">Conclusion</span></strong><span style="font-family: Tahoma;"><strong>:</strong> The use of the interferon alpha 2b recombinant was safe in the treatment of the multiple sclerosis in these patients.</span></p><p class="MsoNormal"> </p>http://medisur.sld.cu/index.php/medisur/article/view/288interferón-alfa 2bensayos clínicosesclerosis múltiple
spellingShingle Leslie Pérez Ruiz
Ana María Ramos Cedeño
José Cabrera Gómez
Nancy Echazábal Santana
Hailen Bobillo López
Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
Medisur
interferón-alfa 2b
ensayos clínicos
esclerosis múltiple
title Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
title_full Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
title_fullStr Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
title_full_unstemmed Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
title_short Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
title_sort intensive farmaco surveillance of interferon alpha 2b recombinant in multiple sclerosis
topic interferón-alfa 2b
ensayos clínicos
esclerosis múltiple
url http://medisur.sld.cu/index.php/medisur/article/view/288
work_keys_str_mv AT leslieperezruiz intensivefarmacosurveillanceofinterferonalpha2brecombinantinmultiplesclerosis
AT anamariaramoscedeno intensivefarmacosurveillanceofinterferonalpha2brecombinantinmultiplesclerosis
AT josecabreragomez intensivefarmacosurveillanceofinterferonalpha2brecombinantinmultiplesclerosis
AT nancyechazabalsantana intensivefarmacosurveillanceofinterferonalpha2brecombinantinmultiplesclerosis
AT hailenbobillolopez intensivefarmacosurveillanceofinterferonalpha2brecombinantinmultiplesclerosis